Gene hunt: why does sunitinib work differently in kidney cancer patients?

NCT ID NCT02404584

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study enrolled 43 people with kidney cancer who were starting sunitinib (Sutent). Researchers measured the drug's level in the blood and checked for genetic differences that might affect how the body processes it. The goal was to understand why sunitinib levels vary from person to person, which could eventually help tailor dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunitinib (Sutent)
What this could lead to: If successful, this could help doctors personalize sunitinib dosing for kidney cancer patients to improve effectiveness.
What could go wrong: This is a small, observational study that only measures drug levels and genes. It does not test a new treatment or change in care, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY NEOPLASMS

Contacts and locations

Show contact details

Locations

CHRU de Montpellier - Hôpital Saint-Eloi

Montpellier, 34295, France
CHRU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France
Institut de Cancérologie du Gard (ICG)

Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.